
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 69,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to block and remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/contact-us/find-local-information.html For other customer complaints, please contact us here: https://www.novonordisk.com/contact-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html
Novo Nordisk의 시장 확장을 추적하고 있습니다
최근 90일간 시그널 315건.
Novo Nordisk의 글로벌 확장이 경쟁사와 비교해 어떤지
막대는 비교 대상 회사 간 상대적 규모를 나타냅니다.
열5| 회사 | 시장 | 신규 시장 | 모멘텀 | 활동 | 확장 점수 |
|---|---|---|---|---|---|
Novo Nordisk본 회사 | 0 | 0 | — | 0 | 0 |
Supervisor, Business Intelligence
공고 보기Taipei, Taipei City, Taiwan · 오늘
Senior IT/OT Solution Architect - API Expansion
공고 보기Kalundborg, Region Zealand, Denmark · 오늘
Pharma Field Sales - Cardiometabolic Care Specialist I - P Bakersfield North California
공고 보기Bakersfield, CA · 5일 전
Talk to a doctor
종료됨Talk to a doctor
종료됨Talk to a doctor
종료됨브라질 제약회사 EMS는 6월 15일 국산 세마글루타이드를 출시하며, 가격은 펜당 R$452로 Ozempic 등 수입품보다 30% 저렴해 비만 치료 접근성을 높입니다.
Caliway Biopharma가 ADA 2026에서 CBL-514 동물 실험 데이터 발표. GLP-1/RA 약물 병용 시 체중 반등 2.7배 감소, 간 지방 106.7% 추가 감소.
노보 노디스크가 중국에서 소그로야(소마파시탄)를 출시. 2.5세 이상 성장호르몬 결핍 아동을 위한 주 1회 투여 장시간 작용 성장호르몬으로 혁신적인 지방산 기술과 PEG 제로 제형이 특징.
인증된 이메일과 직통 전화 잠금 해제
무료 · 신용카드 불필요
Novo Nordisk의 사업, 시장, 성장 시그널에 대한 빠른 답변입니다.

© 2026 Pubrio. 모든 권리 보유.